According to the IMARC Group, the Prader-Willi syndrome market reached a value of USD 639.9 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1,302.9 Million by 2035, exhibiting a growth rate (CAGR) of 6.68% during 2025-2035. This can be attributed to the emerging popularity of intranasal selective oxytocin receptors, since they can aid in appetite regulation and improve social functioning, reduce repetitive behaviors, as well as address hyperphagia in patients.

Prader-Willi syndrome represents a rare genetic disorder that occurs due to the loss of specific genes on chromosome 15, which are usually inherited from the father. The Prader-Willi syndrome market is experiencing notable growth due to the rising awareness about genetic disorders among healthcare professionals and the public, which is fostering early diagnosis and intervention, significantly enhancing patient outcomes. Besides this, advancements in genetic testing technologies, such as chromosomal microarray analysis and next-generation sequencing, are facilitating accurate identification of the disorder, increasing the demand for diagnostic solutions, further augmenting the Prader-Willi syndrome market expansion.

Request for a sample of this report: https://www.imarcgroup.com/prader-willi-syndrome-market/requestsample

Countries Covered:

• United States

• Germany

• France

• United Kingdom

• Italy

• Spain

• Japan

Analysis Covered Across Each Country:

• Historical, current, and future epidemiology scenario

• Historical, current, and future performance of the Prader-Willi Syndrome Market

• Historical, current, and future performance of various therapeutic categories in the market

• Sales of various drugs across the Prader-Willi Syndrome Market

• Reimbursement scenario in the market

• In-market and pipeline drugs

This report also provides a detailed analysis of the current Prader-Willi Syndrome Market drugs and late-stage pipeline drugs.

In-Market Drugs:

• Drug Overview

• Mechanism of Action

• Regulatory Status

• Clinical Trial Results

• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

• Drug overview

• Mechanism of action

• Regulatory status

• Clinical trial results

• Drug uptake and market performance

Competitive Landscape with key players:

The competitive landscape of the Prader-Willi Syndrome Market has been studied in the report with the detailed profiles of the key players operating in the market.

Pfizer

Sandoz

Soleno Therapeutics

Harmony Biosciences

Acadia Pharmaceuticals

ConSynance Therapeutics

Aardvark Therapeutics

Ask the Analyst for Customization and Explore the Full Report with TOC: https://www.imarcgroup.com/prader-willi-syndrome-market

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us: IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research